Lanreotide autogel therapy in patients with acromegaly - current role and perspectives for the future
2010
Abstract
Lanreotide Autogel, a long-acting somatostatin analogue, normalizes growth hormone and insulin-like growth factor I levels in about 50% of patients with acromegaly and causes tumour volumes to shrink by more than 20% in 72-85% of them. It has the advantage of being available in convenient pre-filled syringe and it can be injected subcutaneously by patients or their care-givers/partners.
The efficacy of lanreotide can be increased by combination with dopamine agonists.